Recent News

• 04.23.2025 - Aligos Therapeutics Announces Eight Abstracts Accepted for Presentation at the EASL Congress 2025
• 03.29.2025 - ALG-055009, a Novel Thyroid Hormone Receptor Beta (THR-β) Agonist, was Well-tolerated with Significant Reductions in Liver Fat at Week 12 in Non-cirrhotic MASH Patients in the Randomized, Double-Blind, Placebo-controlled Phase 2a HERALD Study
• 03.29.2025 - Monotherapy with the Capsid Assembly Modulator ALG-000184 Results in High Viral Suppression Rates in Untreated HBeAg-Positive Subjects with Chronic Hepatitis B Virus Infection
• 03.26.2025 - Aligos Therapeutics Presents Positive Data at APASL 2025
• 03.14.2025 - Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
• 03.10.2025 - Aligos Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2024 Financial Results
• 03.03.2025 - Aligos Therapeutics to Announce 4th Quarter 2024 Financial Results on March 10, 2025

Recent Filings

• 04.16.2025 - PRE 14A Other preliminary proxy statements
• 04.03.2025 - EFFECT Notice of Effectiveness
• 04.03.2025 - 424B3 Prospectus [Rule 424(b)(3)]
• 03.27.2025 - S-3 Registration statement under Securities Act of 1933
• 03.12.2025 - SCHEDULE 13D/A General Statement of Acquisition of Beneficial Ownership
• 03.10.2025 - 10-K Annual report [Section 13 and 15(d), not S-K Item 405]
• 03.10.2025 - S-8 Securities to be offered to employees in employee benefit plans
• 03.10.2025 - 8-K Current report
• 03.10.2025 - EX-99.1 EX-99.1
• 03.04.2025 - 4 Statement of changes in beneficial ownership of securities